Cognition Therapeutics, Inc. CGTX 深 滬
已收盤 02-06 16:00:00 美东时间
1.06
+0.060
+6.03%
華盛通- 最 高1.08
- 今 開1.00
- 成交量 97.36万股
- 最 低 0.9998
- 昨 收 0.9997
- 總市值 9357.07万
- 52周最高 3.83
- 市盈率 靜 --
- 換手率 1.10%
- 52周最低 0.2223
- 委 比 85.68%
- 總股本 8827.43万
- 歷史最高 13.80
- 量 比 0.83
- 振 幅 8.02%
- 歷史最低 0.2223
- 每 手 1
- 風險率 0.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cognition Therapeutics Extends Duration Of Expanded Access Program For Dementia With Lewy Bodies
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expanded access program
02-05 20:40
Cognition Therapeutics Meets With FDA to Plan Mid-Stage Trial for Lewy Body Dementia Drug
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food and Drug
01-27 20:37
Cognition Therapeutics Study On Phase 2 Trial Of Zervimesine In Patients With Mild-to-Moderate Dementia With Lewy Bodies Meets Primary Endpoint Of Safety, Tolerability
Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, "Phase 2 Study of Zervimesine (CT1812) in Participants with Mild-to-Moderate Dementia with Lewy Bodies (DLB)" (doi:
01-06 20:36
Cognition Therapeutics Presented Plans For Registrational Program For Zervimesine In Mild-To-Moderate Alzheimer's Disease
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented plans for a registrational program for zervimesine in
2025-12-01 20:40
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
2025-11-24 11:23
B. Riley Securities Reiterates Buy on Cognition Therapeutics, Raises Price Target to $3
B. Riley Securities analyst William Woods reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and raises the price target from $2 to $3.
2025-11-22 00:10
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
2025-11-20 10:28
Cognition Therapeutics Reaches Target Enrollment Of 540 Patients In Phase 2 START Trial To Evaluate Zervimesine To Treat Early Alzheimer's Disease
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company has reached target enrollment of 540
2025-11-13 20:38
Cognition Therapeutics Q3 EPS $(0.06) Beats $(0.09) Estimate
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is a 76 percent increase over losses of $(0.25) per share
2025-11-06 20:37
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
Cognition Therapeutics, Inc. completed a registered direct offering of 14.7 million shares at $2.05 per share, raising approximately $30 million. Proceeds will support advancing zervimesine, a drug candidate for neurodegenerative disorders like Alzheimer’s disease and dementia with Lewy bodies. Zervimesine targets toxic protein buildup in the brain and has shown promise in clinical studies. The company, focused on CNS therapies, recently announce...
2025-09-02 20:00
